Implant loosening and periprosthetic bone loss remain the most common reasons for revision of primary total hip arthroplasty (THA) in the medium to long term (AOANJRR 2013). The tissue response to polyethylene wear particles is an important cause of periprosthetic bone loss -- osteolysis -- behind acetabular components ([@CIT0020]). Review articles on THAs with conventional polyethylene have confirmed that the greater the amount of polyethylene wear, the higher the incidence of osteolysis ([@CIT0048], [@CIT0020]) and that osteolysis is rare below a linear wear rate of 0.1 mm/year ([@CIT0020]). Research has therefore been focussed on improving the wear properties of polyethylene and on monitoring the in vivo wear of polyethylene liners of acetabular components of THAs by using various radiographic methods.

The introduction of XLPE {#ss1}
========================

The first ultra-high-molecular-weight polyethylene (UHMWPE) that was intentionally gamma irradiated at a high level (100mRad) was first used clinically in 1971 ([@CIT0047]). However, further research into the optimal dose of gamma radiation and its effect on the wear properties of conventional UHMWPE was not performed until the 1990s. Manufacturing methods were developed to crosslink polyethylene by exposing it to gamma or electron beam irradiation and then annealing or remelting the material by thermal treatments ([@CIT0046], [@CIT0054]). In vitro hip simulator studies were able to show that highly crosslinked polyethylene (XLPE) components show significantly reduced wear compared to UHMWPE components ([@CIT0034], [@CIT0044]). Thus, XLPE components were introduced for use in THA surgery in 1998 ([@CIT0036]), and by 2003 XLPE was used in two-thirds of hip arthroplasties in the USA ([@CIT0033]). More recently in Australia, the 2013 annual report of the joint replacement registry reported that XLPE was used in 94% of all primary THAs incorporating a PE bearing ([@CIT0001]). When used in primary THA, XLPE has a lower rate of revision for any reason than conventional PE ([@CIT0001]). Different companies continue to use different manufacturing methods for each XLPE product, aiming to balance resistance to wear, oxidation, and fatigue fracture ([@CIT0049]). Ideally, as with all new prosthetic components, new XLPEs should be rigorously tested in clinical trials before being released for general use because of potential variation in manufacturing methods, which may lead to possible failure ([@CIT0050], [@CIT0040]).

The in vivo wear rate of XLPE acetabular components has been shown to be less than that of conventional UHMWPE components ([@CIT0043], [@CIT0036], [@CIT0037]). However, the wear rates reported for XLPE components have varied considerably between different published studies ([@CIT0036]). For example, the mean 2D wear rate of one type of XLPE liner, using different measurement techniques after 5 years or more, has varied between 0.01 and 0.05 mm/year ([@CIT0022], [@CIT0004], [@CIT0045], [@CIT0023], [@CIT0010]).

Methods of wear measurement {#ss2}
===========================

Clinical studies of bearing surfaces use serial radiographs to measure the amount of femoral head penetration within the acetabular component as a representation of wear of the bearing surface. Traditionally, plain anteroposterior and/or lateral radiographs have been taken at regular time points postoperatively and the measurements have been made either manually (Livermore method ([@CIT0038]); Dorr and Wan method ([@CIT0019])) or using a software program that analyzes digitized radiographs (Martell's "Hip Analysis Suite" ([@CIT0041]); Devane's "PolyWare" ([@CIT0014], [@CIT0015])). Measurements made from plain radiographs were sensitive enough to measure wear of conventional UHMWPE. However, due to the improved wear properties of XLPE, measurement of the lower amounts of in vivo wear associated with XLPE is more challenging, ideally requiring a more sensitive measurement method---namely radiostereometric analysis (RSA) ([@CIT0007], [@CIT0053]) .

Radiostereometric analysis {#ss3}
==========================

RSA uses dual simultaneous radiographs taken over a calibration cage to calculate the 3D movement of one skeletal body segment relative to another ([@CIT0032]). The traditional RSA method relies on the implantation of small spherical tantalum markers (0.8 and 1.0 mm diameter) to represent each skeletal body of interest ([@CIT0031]). RSA was first used to measure polyethylene wear in 1976 ([@CIT0003]). To measure polyethylene wear, tantalum markers are usually implanted in the peripheral rim of the polyethylene liner or on the back side of the cemented polyethylene components at the time of surgery, or (for a small number of studies) at the time of manufacture. The patient then undergoes consecutive radiographic examinations at set time points to measure the penetration of the femoral head within the polyethylene component. Accuracy of RSA under optimal conditions has been reported to 33, 22, 86, and 55 µm for measurement of medial, proximal, anterior, and 3D wear, respectively ([@CIT0006]).

If the influences of patient and implant factors on wear rates of XLPE are to be investigated in detail, ideally it should be through meta-analysis of RSA studies. Before a meta-analysis, the published literature must be surveyed to determine whether the data reported in primary studies are sufficient to enable comparison of such factors. Scoping review is a method of inquiry similar to a systematic review but with the distinct aim of assessing the quantity and scope of the research studies conducted on a certain topic ([@CIT0027], [@CIT0055]). We therefore undertook a scoping review of studies on wear of XLPE acetabular components measured by RSA, using a systematic search to identify these studies.

Methods {#ss4}
=======

A systematic search of the published literature in PubMed, Scopus, and Cochrane databases was performed on December 19, 2013. Title, abstract, and keyword fields were queried using the following keywords and index terms in the databases where applicable: "radiostereometric" AND "wear"; "radiostereometric" AND "polyethylene"; "radiostereometry" AND "wear"; "radiostereometry" AND "polyethylene"; "rsa" AND "wear"; "rsa" AND "polyethylene"; "stereophotogrammetric" AND "wear"; "stereophotogrammetric" AND "polyethylene" ([Figure 1](#F1){ref-type="fig"}). These search terms were chosen based on the different names used to describe RSA studies. Publications in English were included if they reported the wear of XLPE, as measured by RSA, in either cemented or uncemented acetabular components in primary THAs. All such studies were included in this review, as the aim of scoping reviews is to determine the extent of the literature on a certain topic and therefore, unlike meta-analyses or systematic reviews, exclusion based on critical appraisal of methodological quality is not required. Polyethylene components were defined as highly crosslinked when intentionally treated using a total radiation dose ranging from 50 to 105 kGy ([@CIT0035]). Duplicate publications, theses, case reports, conference proceedings, and abstracts were all excluded. Data extracted from the studies included details of the patient cohort, the RSA methodology used, precision, total femoral head penetration, bedding-in/creep, and wear.

![Flow chart of the systematic search performed of the PubMed, Scopus, and Cochrane databases.](ORT-86-159-g001){#F1}

Results {#ss5}
=======

We found 18 publications ([Table 1](#T1){ref-type="table"}) that fitted the criteria (Figure), representing 12 independent cohorts of patients. 9 of the 18 publications ([@CIT0017], [@CIT0018], [@CIT0051], [@CIT0026], [@CIT0056], [@CIT0029], [@CIT0052], [@CIT0010],[@CIT0011]) were longer-term follow-up reports of these cohorts. The wear of 7 different XLPE components was measured, incorporating 3 designs of cemented XLPE acetabular components and 4 designs of XLPE liners of uncemented acetabular components, as detailed in [Table 1](#T1){ref-type="table"}. 10 of the 12 cohorts received 28-mm articulations, and 2 cohorts involved larger articulations (32-mm and 36-mm). The material of the femoral head was cobalt chromium in 8 cohorts and oxidized zirconium in one. The material was not reported for 3 cohorts.

###### 

Implants used in each patient cohort

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cohort   Publication    XLPE component                                              Head size, mm   Head material            Femoral component
  -------- -------------- ----------------------------------------------------------- --------------- ------------------------ --------------------------------------------
  1        [@CIT0016];    Durasul (Zimmer)                                            28              CoCr                     Spectron (Smith & Nephew)

            [@CIT0017];                                                                                                        

            [@CIT0018];                                                                                                        

            [@CIT0029]                                                                                                         

  2        [@CIT0017];    Longevity liner within Trilogy shell (Zimmer)               28              CoCr                     Spectron (Smith & Nephew)

            [@CIT0018]                                                                                                         

  3        [@CIT0050];    Osteonics Cup made of Crossfire PE (Stryker Orthopaedics)   28              CoCr                     Exeter Femoral Stem (Stryker Orthopaedics)

            [@CIT0051];                                                                                                        

            [@CIT0052]                                                                                                         

  4        [@CIT0059]     XLPE 10 within Reflection Shell (Smith and Nephew)          28              CoCr                     Spectron (Smith & Nephew)

  5        [@CIT0009]     Longevity liner within Trilogy Shell (Zimmer)               28              NR                       NR

  6        [@CIT0009]     Longevity liner within Trilogy Shell (Zimmer)               36              NR                       NR

  7        [@CIT0025];    Longevity liner within Trilogy Shell (Zimmer)               28              CoCr                     CPT (Zimmer)

            [@CIT0026];                                                                                                        

            [@CIT0056]                                                                                                         

  8        [@CIT0002]     Longevity liner within Trilogy Shell (Zimmer)               28              NR                       ML Taper (Zimmer)

  9        [@CIT0012];    Marathon liner within Pinnacle Shell\                       28              CoCr                     Corail (Depuy Orthopaedics)
                          (Depuy Orthopaedics)                                                                                 

            [@CIT0010]                                                                                                         

  10       [@CIT0013];    X3 liner within Trident Shell                               32              CoCr                     Accolade

            [@CIT0011]    (Stryker Orthopaedics)                                                      (Stryker Orthopaedics)   

  11       [@CIT0030]     Reflection All-Poly XLPE (Smith & Nephew)                   28              CoCr                     Spectron EF (Smith & Nephew)

  12       [@CIT0030]     Reflection All-Poly XLPE (Smith & Nephew)                   28              Oxinium                  Spectron EF (Smith & Nephew)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR: not reported.

Collectively, RSA results have been reported for a maximum of 260 THAs ([Table 2](#T2){ref-type="table"}). The initial report of each cohort was published at either 2 or 3 years, and the longest follow-up was 10 years. The age of each cohort at THA varied between a mean or median of 48 and 72 years.

###### 

Details of RSA studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cohort   Age (range)          Number of patients   Follow-up, months              Report   Years of follow-up   Number of patients included in RSA results                  Software       Acetabular reference   Standing/Supine
  -------- -------------------- -------------------- ------------------------------ -------- -------------------- ----------------------------------------------------------- -------------- ---------------------- -----------------------------------------
  1        Median 54 (35--68)   31                   within 7 days,                 1st      2                    ([@CIT0016]); 23 supine, 21 standing                        UmRSA          B                      Supine [**^a^**](#T2-F1){ref-type="fn"}

                                                     3, 6, 12, 24, 36               2nd      3                    ([@CIT0017]); 20 supine, 18 standing                                                              

                                                     60, 84, 120                    3rd      5                    ([@CIT0018]); 28 supine, 22 standing                                                              

                                                                                    4th      10                   ([@CIT0029]); 23 supine                                                                           

  2        Median 48 (29--70)   32                   within 7 days, 3,              1st      2                    ([@CIT0017]); 22 supine, 20 standing                        UmRSA          B                      Supine [**^a^**](#T2-F1){ref-type="fn"}

                                                     6, 12, 24, 36, 60              2nd      5                    ([@CIT0018]); 19 supine, 12 standing                                                              

  3        Mean 58 (49--79)     10                   within 7 days,                 1st      3                    ([@CIT0050]); 10                                            UmRSA          B                      Supine

                                                     2, 12, 24, 36, 60,             2nd      6                    ([@CIT0051]); 9                                                                                   

                                                     72, 120                        3rd      10                   ([@CIT0052]); 8                                                                                   

  4        Mean 68 (53--83)     30                   3 to 7 days, 2,\               1st      2                    ([@CIT0059]); 28                                            UmRSA 6.0      B+E                    Supine
                                                     12, 24                                                                                                                                                         

  5        Mean 56 (36--77)     16                   6 weeks, 6, 12,\               1st      3                    ([@CIT0009]); 16(25/30 [**^b^**](#T2-F2){ref-type="fn"})    UmRSA 6.0      B; B+\                 Standing
                                                     24, 36                                                                                                                                  E; E                   

  6        Mean 56 (36--77)     14                   6 weeks, 6,12,\                1st      3                    ([@CIT0009]); 14 (25/30 [**^b^**](#T2-F2){ref-type="fn"})   UmRSA 6.0      B; B+\                 Standing
                                                     24, 36                                                                                                                                  E; E                   

  7        Mean 68 (52--76)     27                   PO, 3, 6, 12, 24,\             1st\     2                    ([@CIT0025]); 26\                                           Gill et al.\   Un-bedead              Standing
                                                     36, 60, 84                     2nd\                          3 ([@CIT0026]); 26\                                         1998                                  
                                                                                    3rd                           7 ([@CIT0056]); 22                                                                                

  8        Mean 58 (SD 8)       24                   6 weeks, 6, 12, 24             1st      2                    ([@CIT0002]); 24                                            UmRSA          B                      Standing

  9        Median 72 (55--80)   30                   4--6 days, 6, 12, 24, 72       1st\     2                    ([@CIT0012]); 25\                                           UmRSA 6.0      B+E                    Supine
                                                                                    2dn                           6 ([@CIT0010]); 24                                                                                

  10       Median 63 (47--76)   21                   Within 7 days, 6, 12, 24, 60   1st\     2                    ([@CIT0013]); 19\                                           UmRSA 6.0      B+E                    Supine
                                                                                    2nd                           5 ([@CIT0011]); 18                                                                                

  11       Mean 70 (SD 5)       30                   9--15 days, 3, 6, 12, 24       1st      2                    ([@CIT0030]); 29                                            UmRSA 5.0      B                      Supine

  12       Mean 70 (SD 5)       30                   9--15 days, 3, 6, 12, 24       1st      2                    ([@CIT0030]); 24                                            UmRSA 5.0      B                      Supine
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Supine and standing from 3 months.

Combined number of patients included in wear results for cohorts 5 and 6.

B: beaded; B+E: beaded plus ellipse; E: ellipse

The specific RSA methodology used varied between cohorts ([Table 2](#T2){ref-type="table"}). For example, supine radiographs were used for RSA examinations in 6 cohorts, standing in 4, and a combination of both supine and standing in 2. All but 1 of the RSA studies used the UmRSA software package (RSA Biomedical, Umea, Sweden), but with different versions over time. The remaining study used software described by [@CIT0024]. Tantalum beads were implanted within the XLPE component in 11 of 12 cohorts, to represent the acetabular segment. In most cases, RSA radiographs within the first postoperative week were used as the reference examination.

The precision of proximal wear measurements was reported for 6 cohorts and varied from 0.02 to 0.11 mm ([Table 3](#T3){ref-type="table"}). Both proximal and 3D head penetrations were reported for almost all cohorts, but the time over which the wear rate was calculated varied due to the time period allowed for bedding-in, which ranged from 2 to 24 months ([Table 4](#T4){ref-type="table"}). The proximal wear rate calculated after this period of assumed bedding-in ranged from a mean or median of 0.00 to 0.06 mm/year.

###### 

Precision of RSA from double examinations in each cohort

  Cohort      Publication in which precision was reported   Original calculation method        Number of double examinations      Adjusted precision                                                                                       
  ----------- --------------------------------------------- ---------------------------------- ---------------------------------- ---------------------------------- ---------------------------------- ---------------------------------- ----------------------------------
  1           [@CIT0016]                                    99% CI                             45                                 0.10                               0.08                               0.15                               0.17
  2           [@CIT0017]                                    99% CI                             45                                 [**^a^**](#T3-F1){ref-type="fn"}   [**^a^**](#T3-F1){ref-type="fn"}   [**^a^**](#T3-F1){ref-type="fn"}   [**^a^**](#T3-F1){ref-type="fn"}
  3           [@CIT0051]                                    95% CI                             99                                 [**^b^**](#T3-F2){ref-type="fn"}   0.08                               [**^b^**](#T3-F2){ref-type="fn"}   0.16
               [@CIT0052]                                   1.96 × SD                          [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   0.09                               [**^b^**](#T3-F2){ref-type="fn"}   0.31
  4           [@CIT0059]                                    Beaded 1.96 × SD                   28                                 [**^b^**](#T3-F2){ref-type="fn"}   0.08                               [**^b^**](#T3-F2){ref-type="fn"}   0.22
                                                            Ellipse 1.96 × SD                  28                                 [**^b^**](#T3-F2){ref-type="fn"}   0.10                               [**^b^**](#T3-F2){ref-type="fn"}   0.28
  5 and 6     [**^b^**](#T3-F2){ref-type="fn"}              [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}
  7           [**^b^**](#T3-F2){ref-type="fn"}              [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}
  8           [**^b^**](#T3-F2){ref-type="fn"}              [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}
  9           [@CIT0012]                                    95% CI                             22                                 0.03                               0.02                               0.07                               [**^b^**](#T3-F2){ref-type="fn"}
  10          [**^b^**](#T3-F2){ref-type="fn"}              [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}   [**^b^**](#T3-F2){ref-type="fn"}
  11 and 12   [@CIT0030]                                    2.009 × SD                         50                                 0.11                               0.11                               0.33                               0.21

Precision not specified for each axis, "between 0.07 and 0.32 mm".

Not reported.

###### 

Proximal and 3D femoral head penetration, bedding-in, and wear rate reported for each cohort in each follow-up report

  Cohort         Follow-up years   Femoral head penetration[**^a^**](#T4-F1){ref-type="fn"} (mm)            Bedding-in[**^b^**](#T4-F2){ref-type="fn"} mm                             Wear rate[**^c^**](#T4-F3){ref-type="fn"} mm/year
  -------------- ----------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  **Proximal**                                                                                                                                                                        
  1              2 ([@CIT0016])    0.13 (0.03 to 0.31) [**^d^**](#T4-F4){ref-type="fn"}                     0.1 [**^d^**](#T4-F4){ref-type="fn"}                                      0.03 [**^f^**](#T4-F6){ref-type="fn"} (3--24 m) [**^e^**](#T4-F5){ref-type="fn"}
                 3 ([@CIT0017])    0.13 (-0.02 to 0.30) [**^d^**](#T4-F4){ref-type="fn"}                    0.1 [**^d^**](#T4-F4){ref-type="fn"}, [**^g^**](#T4-F7){ref-type="fn"}    0.03 [**^f^**](#T4-F6){ref-type="fn"} (3--36 m) [**^e^**](#T4-F5){ref-type="fn"}
                 5 ([@CIT0018])    0.15 (-0.10 to 0.86) [**^d^**](#T4-F4){ref-type="fn"}                    0.1 [**^d^**](#T4-F4){ref-type="fn"}, [**^g^**](#T4-F7){ref-type="fn"}    0.02 [**^f^**](#T4-F6){ref-type="fn"} (3--60 m) [**^e^**](#T4-F5){ref-type="fn"}
                 10 ([@CIT0029])   0.15 [**^g^**](#T4-F7){ref-type="fn"}                                    0.1 [**^d^**](#T4-F4){ref-type="fn"}, [**^g^**](#T4-F7){ref-type="fn"}    0.01 (SE 0.00) (2--10 yr) [**^d^**](#T4-F4){ref-type="fn"}
  2              2 ([@CIT0017])    0.08 (-0.03 to 0.28) [**^d^**](#T4-F4){ref-type="fn"}                    0.08 [**^d^**](#T4-F4){ref-type="fn"}                                     0.03 [**^f^**](#T4-F6){ref-type="fn"} (3--24 m) [**^e^**](#T4-F5){ref-type="fn"}
                 5 ([@CIT0018])    0.08 (-0.02 to 0.24) [**^d^**](#T4-F4){ref-type="fn"}                    0.08 [**^d^**](#T4-F4){ref-type="fn"}, [**^g^**](#T4-F7){ref-type="fn"}   0.02 [**^f^**](#T4-F6){ref-type="fn"}(3--60 m) [**^e^**](#T4-F5){ref-type="fn"}
  3              3 ([@CIT0050])    NR                                                                       0.05 (0--2 months)                                                        0.01 (2--24 m)
                 6 ([@CIT0051])    0.08 (CI 0.02 to 0.13)                                                   0.06 [**^g^**](#T4-F7){ref-type="fn"}                                     0.01 (2--72 m)
                 10 ([@CIT0052])   0.07 (CI -0.02 to 0.15)                                                  0.06 [**^g^**](#T4-F7){ref-type="fn"}                                     0.00 (2--120 m)
  4              2 ([@CIT0059])    0.07 [**^g^**](#T4-F7){ref-type="fn"}                                    0.06 [**^g^**](#T4-F7){ref-type="fn"}                                     0.01 (2--24 m)
  5              3 ([@CIT0009])    0.06 [**^h^**](#T4-F8){ref-type="fn"} (SE 0.03)                          0.06 [**^h^**](#T4-F8){ref-type="fn"} (SE 0.04)                           0.03 [**^h^**](#T4-F8){ref-type="fn"} (SE 0.02)
  6              3 ([@CIT0009])    0.06 [**^h^**](#T4-F8){ref-type="fn"} (SE 0.06)                          0.07 [**^h^**](#T4-F8){ref-type="fn"} (SE 0.02)                           0.00 [**^h^**](#T4-F8){ref-type="fn"} (SE 0.06)
  7              2 ([@CIT0025])    NR                                                                       NR                                                                        0.06 (SD 0.07) (3--24 m)
                 3 ([@CIT0026])    NR                                                                       0.17 [**^g^**](#T4-F7){ref-type="fn"}                                     0.02 [**^g^**](#T4-F7){ref-type="fn"}
                 7 ([@CIT0056])    NR                                                                       NR                                                                        0.01 (CI ±0.03)
  8              2 ([@CIT0002])    0.07 [**^h^**](#T4-F8){ref-type="fn"} (-0.04 to 0.19)                    0.07 [**^h^**](#T4-F8){ref-type="fn"} (-0.14 to 0.16)                     0.02 [**^g^**](#T4-F7){ref-type="fn"}
  9              2 ([@CIT0012])    0.12 (-0.10 to 0.38)                                                     0.11 (-0.01 to 0.39)                                                      0.01
                 6 ([@CIT0010])    0.19 (0.00 to 0.51)                                                      0.11 (-0.01 to 0.39)                                                      0.01 (-0.02 to 0.06)
   10            2 ([@CIT0013])    0.02 [**^h^**](#T4-F8){ref-type="fn"} (-0.07 to 0.16)                    0.01 [**^h^**](#T4-F8){ref-type="fn"} (-0.09 to 0.12)                     0.02 [**^h^**](#T4-F8){ref-type="fn"}
                 5 ([@CIT0011])    0.02 (-0.11 to 0.13)                                                     0.01 (-0.09 to 0.12)                                                      0.00 (-0.03 to 0.03)
   11            2 ([@CIT0030])    0.09 (CI 0.06--0.12)                                                     0.06 [**^g^**](#T4-F7){ref-type="fn"}                                     0.03
   12            2 ([@CIT0030])    0.08 (CI 0.04--0.12)                                                     0.06 [**^g^**](#T4-F7){ref-type="fn"}                                     0.02
  **3D**                                                                                                                                                                              
  1              2 ([@CIT0016])    0.18 (0.07--0.35) [**^d^**](#T4-F4){ref-type="fn"}                       0.15 [**^d^**](#T4-F4){ref-type="fn"}                                     0.11 [**^f^**](#T4-F6){ref-type="fn"} (3--24 m) [**^e^**](#T4-F5){ref-type="fn"}
                 3 ([@CIT0017])    0.23 (0.04--0.41) [**^d^**](#T4-F4){ref-type="fn"}                       0.18 [**^d^**](#T4-F4){ref-type="fn"},[**^g^**](#T4-F7){ref-type="fn"}    0.09 [**^f^**](#T4-F6){ref-type="fn"} (3--36 m) [**^e^**](#T4-F5){ref-type="fn"}
                 5 ([@CIT0018])    0.23 (0.02--0.91) [**^d^**](#T4-F4){ref-type="fn"}                       NR                                                                        0.04 [**^f^**](#T4-F6){ref-type="fn"} (3--60 m) [**^e^**](#T4-F5){ref-type="fn"}
                 10 ([@CIT0029])   0.22 [**^d^**](#T4-F4){ref-type="fn"},[**^g^**](#T4-F7){ref-type="fn"}   0.18 [**^d^**](#T4-F4){ref-type="fn"},[**^g^**](#T4-F7){ref-type="fn"}    0.01 [**^f^**](#T4-F6){ref-type="fn"} (SE 0.00) (2--10 yr) [**^d^**](#T4-F4){ref-type="fn"}
  2              2 ([@CIT0017])    0.22 (0.05--0.40) [**^d^**](#T4-F4){ref-type="fn"}                       0.25 (supine)                                                             0.19 [**^f^**](#T4-F6){ref-type="fn"}(3--24 m) [**^e^**](#T4-F5){ref-type="fn"}
                 5 ([@CIT0018])    0.20 (0.10--0.61) [**^d^**](#T4-F4){ref-type="fn"}                       0.24 (supine)                                                             0.07 [**^f^**](#T4-F6){ref-type="fn"}(3--60 m) [**^e^**](#T4-F5){ref-type="fn"}
  3              3 ([@CIT0050])    0.17 (CI 0.06--0.28)                                                     NR                                                                        NR
                 6 ([@CIT0051])    0.23 (CI 0.10--0.35)                                                     NR                                                                        0.03 (2--72 m)
                 10 ([@CIT0052])   0.20 (CI 0.03--0.36)                                                     0.19 [**^g^**](#T4-F7){ref-type="fn"}                                     0.00 [**^f^**](#T4-F6){ref-type="fn"}(2--120 m)
  4              2 ([@CIT0059])    0.19 [**^g^**](#T4-F7){ref-type="fn"}                                    0.15 [**^g^**](#T4-F7){ref-type="fn"}                                     0.03 [**^f^**](#T4-F6){ref-type="fn"}(2--24 m)
  5              3 ([@CIT0009])    NR                                                                       NR                                                                        NR
  6              3 ([@CIT0009])    NR                                                                       NR                                                                        NR
  7              2 ([@CIT0025])    0.31 (SD 0.18)                                                           0.30 [**^g^**](#T4-F7){ref-type="fn"}                                     0.06 (SD 0.06) (3--24 m)
                 3 ([@CIT0026])    0.35 (SD 0.14)                                                           0.26 (SD 0.17)                                                            0.03 (SD 0.06)
                 7 ([@CIT0056])    0.33 (CI ± 0.10)                                                         0.29 (95% CI ±0.07)                                                       0.01 (CI ± 0.02)
  8              2 ([@CIT0002])    NR                                                                       NR                                                                        NR
  9              2 ([@CIT0012])    0.23 (0.02--0.84)                                                        0.23 (0.06 to 0.93)                                                       0.00 [**^f^**](#T4-F6){ref-type="fn"}
                 6 ([@CIT0010])    0.32 (0.05--0.60)                                                        0.23 (0.06 to 0.93)                                                       0.018 (-0.11 to 0.08)
   10            2 ([@CIT0013])    0.16 [**^h^**](#T4-F8){ref-type="fn"} (0.07--0.26)                       0.16 [**^h^**](#T4-F8){ref-type="fn"} (0.02 to 0.32)                      -0.04 [**^h^**](#T4-F8){ref-type="fn"}
                 5 ([@CIT0011])    0.15 (0.04--0.32)                                                        0.19 (0.02 to 0.32)                                                       -0.01 (-0.06 to 0.04)
   11            2 ([@CIT0030])    0.19 (CI 0.15--0.23)                                                     NR                                                                        NR
   12            2 ([@CIT0030])    0.18 (CI 0.13--0.22)                                                     NR                                                                        NR

CI: 95% confidence interval

NR: not reported.

Initial to final follow-up unless otherwise noted; mean (range).

Initial examination to 1-year follow-up unless otherwise noted; mean (range).

Annual rate from 1-year follow-up to final follow-up unless otherwise noted; mean (range).

Supine

Standing

Manually calculated to be rate/year from a reported value given after bedding-in.

Visualized from graph

Median

Discussion {#ss6}
==========

New materials, such as XLPE components used in THA, need to be closely monitored as part of their stepwise introduction into clinical use ([@CIT0039], [@CIT0040]). The wear rates reported for XLPE components varied between studies. Some of this variation is likely to be due to the different measurement methods used ([@CIT0036]). However, some variation could also be due to variables that include patient factors such as BMI and activity; implant factors such as femoral head material, liner thickness, and manufacturing methods for XLPE; and surgical factors such as inclination angle of the acetabular component. Thus, while the wear rate of XLPE acetabular components has been shown to be substantially less than that of conventional UHMWPE components ([@CIT0036], [@CIT0037], [@CIT0043]), the possible influence of the above variables remains unclear. Although a meta-analysis would be required to investigate the influence of these variables on wear rates of XLPE, the number of patients required for a meta-analysis would greatly exceed that included in the current literature, due to the low wear of XLPE and the relatively weak effect of such variables on wear. Our scoping review identified a relatively small number of studies that had measured the wear of XLPE components using the most sensitive measure available, namely RSA. Overall, the studies examined 12 cohorts involving only 260 THAs. By recommending further guidelines to standardize the reporting of RSA wear studies, we hope that this will assist retrospective analysis of the influence of these factors in the future.

Methodology of RSA studies {#ss7}
==========================

Cohort size {#ss8}
-----------

All of the cohorts had a sample size of between 10 and 32 at recruitment. As RSA has been demonstrated to have high sensitivity ([@CIT0006]), statistical power can be achieved with fewer observations and therefore a small sample size is not, in itself, necessarily a methodological limitation. However, most studies had decreasing sample sizes over time. Missing or poor-quality RSA examinations further reduced the size of the originally recruited cohort, after exclusions for death and other reasons for loss to follow-up. This common problem of decreasing availability of RSA data over time must be considered when designing RSA-based clinical trials, especially if longer-term follow-up is required.

Follow-up time points {#ss9}
---------------------

Follow-up time points within the first year varied between the RSA studies, thereby potentially influencing the amount of femoral head penetration recorded. The first reference RSA examination was usually performed within the first week postoperatively. However, some studies used 11--15 days, 2 weeks, or 6 weeks as their baseline examination. This may influence both bedding-in and femoral head penetration measurements. How bedding-in and wear varies between different types of XLPE components remains unknown. The amount of initial plastic (permanent) deformation of the polyethylene liner may differ due to design, manufacturing error, fit of the liner within the shell, elasticity of the metal shell, and surface of the inner shell. Bedding-in may also differ between cemented XLPE components and XLPE liners within uncemented metal shells.

RSA software and acetabular reference segment {#ss10}
---------------------------------------------

The specific manner in which RSA was undertaken also varied between the studies, and may therefore also affect the outcome of meta-analyses. Early versions of the UmRSA software required the implantation of tantalum markers in the polyethylene, and subsequently measured the movement of the center of the femoral head within the rigid body defined by the markers in the polyethylene. A recent modification to the UmRSA software allows metal-backed hemispherical acetabular components to be measured using an ellipse algorithm ([@CIT0005]). Therefore, the movement of the femoral head can be measured within the ellipse of the metal acetabular components or by using beads in the liner, or by using a combination of both methods (beaded plus ellipse) ([@CIT0005]). The study that used Gill's software ([@CIT0024]) used the known dimensions of the prostheses and measured the femoral head penetration relative to the center of the metal acetabular component, this approach being similar to the ellipse-only method. Studies that do not use beads have the potential to save time and money, and also eliminate safety concerns relating to the implantation of beads. Furthermore, there is no exclusion of patients due to insufficiently marked components, which is a common reason for exclusion of hips in beaded analysis ([@CIT0005]). RSA wear measurements in the proximal direction using the ellipse algorithm alone are less precise than those using a beaded reference segment: 0.10 mm and 0.08 mm, respectively ([@CIT0059]). A combination of beads and the ellipse algorithm was found to have the smallest error ([@CIT0005]) and the least amount of variance ([@CIT0009]). To date, only 1 study has presented the results of all 3 different reference segments (beaded, beaded plus ellipse, and ellipse only), and showed only slight variation in the results ([@CIT0009]). However, these different representations of the acetabular reference segment may influence the measurement of early creep and bedding-in if there is early movement between the liner and the metal-backed shell.

Patient positioning {#ss11}
-------------------

Another methodological difference between studies was the use of standing and/or supine positioning during RSA examinations ([Table 2](#T2){ref-type="table"}). Standing radiographs are thought to position the femoral head in the deepest part of its wear track within the polyethylene liner. However, standing radiographs may have poorer image quality due to different soft tissue exposure (stomach overhang) and different pelvic positioning. Patients have also reported that standing examinations caused discomfort at the initial postoperative examination ([@CIT0016]). 3 RSA studies have investigated the differences in measurements made using standing and supine radiographs. Specifically, von [@CIT0058] reported that 3D wear measurements made from supine and standing (i.e. weight-bearing) examinations taken on the same day had a high correlation and there was no difference in the magnitude of penetration. [@CIT0017] also found no difference in the proximal head penetration recorded, while [@CIT0008] found small differences in some wear measurements between standing and supine examinations, but the occurrence was low and did not affect the average results.

Precision reported in RSA studies {#ss12}
---------------------------------

Given the typically low amounts of XLPE wear reported in RSA clinical studies, determination of the precision of the RSA method is important. Despite the RSA-reporting guidelines recommending the inclusion of precision measurements in clinical studies ([@CIT0057]), double examinations to determine precision were undertaken for only 6 of the 12 cohorts. While double examinations give a slight increase in radiation exposure of patients, the precision of RSA measurements cannot be determined using a phantom model ([@CIT0005]). Proximal wear measurements were more precise (range: 0.02--0.11 mm) than 3D wear measurements (range: 0.16--0.28 mm). The RSA method is more precise in the x- and y-axes relative to the z-axis because the latter measurements are made "out of plane" in the uniplanar setup ([@CIT0031]). This will in turn affect the precision of the 3D measurement, namely the vectorial sum of all 3 axes.

Reporting of RSA wear results {#ss13}
-----------------------------

To summarize the wear rate derived from studies identified in this review, the reported results were described using 3 terms: (1) "femoral head penetration" (initial examination to latest follow-up), (2) "bedding-in" (initial examination to the 1-year examination), and (3) "wear rate" (the annual wear rate between the 1-year examination and latest follow-up). RSA provides measurements in 3 axes: proximal-distal, medial-lateral, and anterior-superior. Proximal and 3D (vectorial sum) femoral head penetration and wear rates were most commonly reported, although the axis of measurement was not defined in some publications. Interpretation of the results was further complicated by the use of a number of different terms to denote the same concept. For example, proximal measurements were variously referred to as superior, longitudinal, or linear---and 3D measurements as total, linear, or maximum total point motion (MTPM). Interestingly, the 2D wear rates, which allow comparison of results to those of studies using less sophisticated techniques and plain radiographs, were only reported in 2 cohorts ([@CIT0010], [@CIT0011]).

Mean and median values were commonly reported, but for some publications these figures had to be estimated from graphs or calculated using other data provided in the publication ([Table 4](#T4){ref-type="table"}). Within any one cohort, varying numbers of patients were often included at different follow-up time points, possibly affecting the reported mean wear rate, particularly if patients with wear rates at either end of the range were differentially represented over time. The mean annual proximal wear rate did not exceed 0.06 mm/year for any cohort. Only 2 publications reported mean 3D wear rates above 0.06 mm/year ([@CIT0016], [@CIT0017]). However, because the wear rate in both of these cohorts was calculated between 3 months and the latest follow-up, some of the penetration attributed to wear may in fact have been due to bedding-in. This is supported by the finding that a much lower mean 3D wear rate of 0.005 mm/year was reported for the same cohort between 2 and 10 years ([@CIT0052]). It is therefore important to emphasize that if wear rate is calculated using a reference time point within the bedding-in phase, the reported rate may be an overestimation of the true wear rate. Although the majority of studies used 1 year as the baseline reference for wear rate calculations, the assumed end of bedding-in/creep and the beginning of wear has varied in the literature, ranging from 2 months to 2 years ([@CIT0042]).

Studies of UHMWPE identified that an annual wear rate exceeding 0.1 mm/year was associated with an increased risk of developing osteolysis ([@CIT0020]), and an increased risk of revision surgery due to loosening or lysis. This suggests that the percentage of THAs with wear exceeding certain thresholds is, in fact, of more clinical importance than a mean or median wear rate. It is important to emphasize that the threshold of XLPE wear possibly associated with osteolysis is unknown. Therefore, presentation of scatter plots of individual wear rates, coupled with long-term clinical follow-up of patients, will facilitate a better understanding of the relationship between XLPE wear and subsequent development of osteolysis. Only 4 publications in the current review have reported percentages of patients exceeding specified thresholds ([@CIT0018], [@CIT0056], [@CIT0010], [@CIT0011]). Specifically, 3 reported no patients with a wear rate greater than 0.1 mm/year ([@CIT0056], [@CIT0010], [@CIT0011]) and 1 reported that 24 of 28 patients in cohort 1 had a wear rate of less than 0.05 mm/year and that all patients in cohort 2 had a wear rate below 0.05 mm/year ([@CIT0018]).

Recommendations to improve reporting of RSA wear results {#ss14}
--------------------------------------------------------

13 guidelines were described by [@CIT0057] for standardization of RSA of implants. These guidelines have recently been incorporated within the ISO for measuring migration with RSA (ISO 16087:2013 (E)). The findings of the present scoping review have led to further recommendations of important items that should be included when reporting RSA wear results ([Table 5](#T5){ref-type="table"}). Standardization of the manner in which RSA wear results are presented will enable a better understanding of the effects of surgical and patient factors on wear. Most importantly, such standardization is also likely to facilitate early identification of poorly performing implants.

###### 

Recommendations to enhance reporting of RSA wear results

  ---------------------------------------------------------------------------------------------
  Recommendations to enhance reporting of RSA wear results
  ---------------------------------------------------------------------------------------------
  Methodology

   1 Components used (femoral head size and material; description of XLPE component)

   2 Patient positioning (supine or standing)

   3 Software and acetabular reference segment used

  Results

   4 Allow one year for bedding-in and creep, and report results using the terms:\
    -- femoral head penetration (initial examination to latest follow-up)\
    -- bedding-in (initial examination to the one-year examination)\
    -- wear rate (the annual wear rate between the one-year examination and latest follow-up)

   5 Report axis of measurement (x, y, z, 2D or 3D)

   6 Use scatter plots of wear results to allow identification of outliers
  ---------------------------------------------------------------------------------------------

Future studies on wear using RSA {#ss15}
--------------------------------

Our review has identified that the wear rates reported for XLPE components are low, which is encouraging for continued clinical use. With 1 exception, the mean proximal and 3D annual wear rates decreased when the length of follow-up increased. In the cohort in which this was not the case ([@CIT0012], [@CIT0010]), the liner was manufactured using an irradiation dose at the lower end of the range included as XLPE (50 kGy). Thus, new designs of XLPE components need to be monitored prospectively. Second-generation XLPEs are being introduced rapidly internationally and differ from first-generation XLPEs by being either sequentially irradiated and annealed, mechanically deformed or compressed, or diffused with vitamin E ([@CIT0021]). However, we identified only 1 cohort in which the bedding-in and wear of a second-generation XLPE liner had been investigated ([@CIT0013], [@CIT0011]). In this cohort, the mean proximal bedding-in was lower than that of all first-generation XLPE components (0.007 mm vs. 0.06--0.17 mm).

The low wear rates reported for XLPE have also encouraged the use of larger articulations, which have been shown to reduce the incidence of dislocation within the first year after THA ([@CIT0028]). In Australia, head sizes of 32 mm or more have been increasingly used over the last 5 years in primary THAs with XLPE components ([@CIT0001]). However, the effect of articulation size on XLPE wear rates is poorly understood. To date, only 1 RSA study has compared the wear rates of 28- and 36-mm articulations. Although that study reported no difference at 3 years ([@CIT0009]), it is important to note that this non-randomized comparison included only 25 hips.

Identification of any potential association between patient-related factors such as age, sex, weight, or activity on the one hand and wear of XLPE on the other is desirable. However, such studies require relatively large samples, given the variability in these factors between patients. Individual RSA studies are limited in this regard due to the costly specialized equipment and analysis required, and to the need for prospective radiographs above a calibration cage. Conversely, although other measurement techniques, such as Martell's Hip Analysis Suite ([@CIT0041]) and PolyWare ([@CIT0014],b), are able to measure the wear rates of larger cohorts retrospectively using plain radiographs, they are limited by their lack of sensitivity. In future, meta-analyses of data pooled from existing RSA studies may provide a means of examining not only the effect of patient-related factors on XLPE wear, but also the relationship between XLPE wear and osteolysis.

Conclusion {#ss16}
----------

Despite the almost universal acceptance of the use of XLPE in acetabular components, to date the publications reporting in vivo wear of XLPE measured using RSA have been based on 12 small cohorts covering only 260 hips. The present scoping review has identified variation in both the methodology and the manner of reporting results of RSA studies. We have made a number of recommendations to enhance the reporting of RSA-based wear results. Longer-term studies are required to determine whether the low wear of XLPE identified in the short term does indeed translate to a low incidence of osteolysis in the medium to long term and, importantly, to a reduction in the need for revision surgery.
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